What happened
Metabiomed reported consolidated results for FY2025: revenue of US$68.6M (+9.5% year on year), operating profit of US$14M (+22.3% year on year) and net income of US$6.17M (−58.5% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$68.6M |
|---|---|
| Revenue vs a year earlier | +9.5% |
| Operating profit | US$14M |
| Net income | US$6.17M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-16, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260316902412 → open original filing |
Source: DART. Information only, not investment advice.